Alnylam’s AI-Diagnosis Play Could Shorten the ATTR-CM Adoption S-Curve—Ignoring the Bottleneck Is a Mistake

The investment case for Alnylam is no longer just about a single drug. It's about the company constructing the fundamental infrastructure to accelerate the adoption curve of its ATTR-CM therapy. The global amyloidosis market is projected to grow from $2.95 billion in 2024 to $6.37 billion by 2033, a 9.2% CAGR. Within this expansion, transthyretin (ATTR) cardiomyopathy is driving the fastest absolute patient growth. Yet the market's primary bottleneck is not treatment efficacy-it's diagnosis. ATTR-CM remains significantly underrecognized, with many patients undiagnosed for years. This creates a classic S-curve adoption challenge: a promising therapy exists, but the patient pipeline is starved.

Alnylam's recent strategic moves directly attack this bottleneck. The FDA approval of its RNAi therapeutic, AMVUTTRA (vutrisiran), for reducing cardiovascular death and hospitalizations validates its disease-modifying potential. Now, the company is building the diagnostic and care coordination rails to convert this clinical promise into exponential market penetration. Its collaboration with Viz.ai aims to leverage AI-powered ECG analysis to detect undiagnosed ATTR-CM patients earlier, moving diagnosis upstream. This is a system-level play to convert rare-disease innovation into routine clinical care.

The setup here is a paradigm shift. Alnylam is transitioning from a pure-play biotech to an integrated care infrastructure provider for a specific, high-need disease. By partnering with technology innovators and national clinical organizations, it's working to improve how ATTR-CM is identified and managed at scale. The goal is to shorten the time from symptom to diagnosis, ensuring patients can access life-prolonging therapies like vutrisiran sooner. In the exponential growth phase of a market, the company that controls the patient identification funnel often captures the dominant share. Alnylam is laying those rails now.

Financial Engine: Funding the Infrastructure Build

The company's financial engine is firing on all cylinders, providing the capital needed to fund its ambitious infrastructure play. For the full fiscal year 2025, Alnylam's combined net product revenue surged to $2.99 billion, an impressive 81% year-over-year growth that significantly exceeded prior guidance. This robust cash flow is the bedrock for its strategic initiatives. The TTR franchise, anchored by AMVUTTRA, is the primary driver, with fourth-quarter sales reaching $859 million and growing at a staggering 151% rate. This isn't just growth; it's the exponential scaling of a market-leading therapy, creating the financial runway to build diagnostic and care coordination systems.

Yet, the path to sustained exponential adoption is not without near-term friction. The company is navigating a few headwinds that will pressure the top line in the coming quarters. A projected mid-single-digit net price decrease for AMVUTTRA in the U.S. and a $25 million decline in international revenues from a German pricing reset are expected to dampen growth sequentially. Furthermore, collaboration revenue is set to decline meaningfully in 2026, with projections of $400 million to $500 million compared to the inflated $727 million seen in 2025, which included a one-time $300 million milestone.

The bottom line is one of disciplined capital allocation. The company is trading some near-term top-line momentum for the long-term goal of accelerating the adoption S-curve. Its healthy gross margins and operating leverage are critical here, allowing it to fund R&D and partnerships without sacrificing its balance sheet. The analyst consensus, with a Buy rating and a price target near $464, reflects confidence that this financial model can support the infrastructure build. The current revenue base provides a powerful buffer, ensuring the company can weather these temporary headwinds while laying the rails for the next phase of exponential patient identification and treatment.

Valuation & Market Reality: Discounting the Future

The market is currently pricing Alnylam as a company in transition, not yet fully crediting the exponential growth path ahead. The stock trades at a PE TTM of 129.6 and a PS TTM of 10.95, a premium that reflects high expectations for future earnings. Yet, the recent price action tells a different story of skepticism. Over the past 120 days, ALNY has declined 31.5%, and it is down 22.9% year-to-date, trading near the lower end of its 52-week range. This disconnect is the classic tension between today's financial reality and tomorrow's technological S-curve.

Analyst forecasts, however, point to a steep correction of that discount. Predictions suggest the stock could rally +403.3% by 2026 and +615.12% by 2030. These numbers aren't about current earnings; they are a bet on the company's ability to accelerate the ATTR-CM adoption curve through its diagnostic infrastructure play. The valuation metrics are high because the market is being asked to look past near-term headwinds-like the sequential price pressure on AMVUTTRA and the collaboration revenue decline-and see the long-term payoff of capturing a much larger patient population.

The current technical setup is neutral to bearish, with the stock consolidating in a range that has seen more selling pressure. The short sale ratio has risen to 16.63%, indicating active skepticism about a near-term rebound. Yet, the underlying financial engine remains strong, with a market cap of $40.67 billion providing a solid base. The key question for investors is whether the current price fully discounts the risk of the infrastructure build failing to accelerate adoption as planned, or if it simply undervalues the magnitude of the paradigm shift Alnylam is attempting to engineer. The stock's steep decline suggests the latter is the prevailing view, leaving significant upside if the company's strategic bets on AI-driven diagnosis and care coordination begin to show results.

Catalysts & Risks: The Adoption Curve's Next Inflection

The investment thesis now hinges on a few key inflection points. The most immediate catalyst is the real-world evidence from the Viz.ai collaboration, which could demonstrate a measurable increase in early ATTR-CM diagnoses and subsequent treatment initiation. While the evidence provided details Viz HCM, the same AI-powered ECG analysis platform is central to Alnylam's strategy for ATTR-CM. The company's partnership with Viz.ai aims to integrate its diagnostic solution into clinical workflows, moving diagnosis upstream. Positive data from this collaboration would validate the infrastructure play, showing it can successfully convert the pipeline of undiagnosed patients into treated ones. This is the core of the S-curve acceleration.

A secondary catalyst is the continued clinical and commercial momentum of the TTR franchise. The recent approval of AMVUTTRA for reducing cardiovascular death and hospitalizations provides a strong treatment anchor. Data from ongoing studies, like the 12-month follow-up from the HELIOS-B open-label extension, will reinforce its long-term efficacy and safety, supporting broader adoption. The pipeline also offers a potential future revenue stream that could extend Alnylam's cardiovascular footprint. The hypertension drug zilebesiran, which showed promise in a Phase 2 study, represents a next-generation RNAi therapeutic for a prevalent condition. Success here would diversify the revenue base beyond rare ATTR-CM, potentially unlocking a much larger addressable market.

The primary risk is the pace of market adoption, which depends entirely on the successful integration of AI diagnostics into the complex reality of clinical workflows. The technology must prove reliable, easy to use, and cost-effective for hospitals and cardiologists to adopt at scale. Any friction in this integration could slow the patient funnel, delaying the exponential growth phase. Competition is another significant risk. The ATTR-CM market is not a duopoly. Other therapies like Onpattro, Vyndaqel, and newer agents are already on the market or in development. Alnylam must defend its market share while simultaneously expanding the total addressable market through better diagnosis. The company's ability to differentiate its therapy and diagnostic platform will be critical.

In essence, the next inflection is about execution. The catalysts are clear: prove the AI diagnosis works, keep the TTR franchise strong, and advance the pipeline. The risks are equally clear: integration friction and competitive pressure. The company is betting that its diagnostic infrastructure can outpace these challenges, converting the current 9.2% CAGR market growth into an exponential adoption curve. The coming year will show if this bet is paying off.